Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-08-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair.

Current evidence established that endothelial progenitor cells (EPC) participate in several models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery disease, etc. However EPC in the setting of PAH is less well established. The target of this study is to demonstrate if the number of EPC is increased in a mexican population of patients with PAH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endothelial Cell Dysfunction in Pulmonary Hypertension

NCT00098072

Secondary Pulmonary Arterial Hypertension

COMPLETED PHASE1

Serum Bio-markers in Pulmonary Hypertension

NCT04472533

Pulmonary Hypertension, Primary, 4

COMPLETED

Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies

NCT02959723

Idiopathic Pulmonary Arterial Hypertension

UNKNOWN

Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension

NCT07176260

Pre-capillary Pulmonary Hypertension

RECRUITING

The Study Of CT Scans and Echo Parameters in Patients With PAH

NCT00625963

Pulmonary Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Idiopathic Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure \>30 mm Hg on right heart catheterization able to walk \>50 m during a standardized 6-min walk test.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients were included in the study if they were in The WHO functional class II to III, and had a mean pulmonary artery pressure \>30 mm Hg on right heart catheterization. The ability to walk \>50 m during a standardized 6-min walk test.

Exclusion Criteria

* Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, major bleeding requiring blood transfusion,renal dysfunction, and evidence for malignant diseases were excluded.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No